

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (currently amended) A method of preparing a dry powder inhalation composition comprising the steps of:

(a) mixing a an inert particulate carrier with a first portion of a first particulate inhalant medicament to form a first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250  $\mu\text{m}$ , wherein the first portion of the first particulate inhalant medicament is sufficient to create a monolayer of the first particulate inhalant medicament on the particulate carrier;

(b) mixing said first mixture with a second particulate inhalant medicament to form a second mixture; and

(c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier.

2. (previously presented) A method according to claim 1, wherein the first portion of the first particulate inhalant

medicament is less than half weight by weight of the total amount of the first particulate inhalant medicament in the dry powder inhalation composition.

3. (previously presented) A method according to claim 1, wherein the first portion of first particulate inhalant medicament is less than 2% weight by weight of the total amount of the particulate carrier.

4. (canceled).

5. (previously presented) A method according to claim 1, wherein the particulate carrier is lactose.

6. (currently amended) A method according to claim 1, wherein the first particulate inhalant medicament is an antiinflammatory steroid or a pharmaceutically acceptable ~~derivative~~ salt, solvate or salt solvate thereof.

7. (currently amended) A method according to claim 1, 5 or 6, wherein the first particulate inhalant medicament is budesonide or a pharmaceutically acceptable ~~derivative~~ salt, solvate or salt solvate thereof.

8. (currently amended) A method according to claim 1 or 5, wherein the second particulate inhalant medicament is a bronchodilator or a pharmaceutically acceptable ~~derivative~~ salt, solvate or salt solvate thereof.

9. (currently amended) A method according to claim 1, 5 or 6, wherein the second particulate inhalant medicament is formoterol or a pharmaceutically acceptable ~~derivative~~ salt, solvate or salt solvate thereof.

10. (previously presented) A method according to claim 1, wherein the ratio of the first particulate inhalant medicament

to the second particulate inhalant medicament by weight is from 5:1 to 100:1.

11. (currently amended) A dry powder inhalation composition prepared by a process comprising the steps of:

- (a) mixing a an inert particulate carrier with a first portion of a first particulate inhalant medicament to form a first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250  $\mu\text{m}$ , wherein the first portion of the first particulate inhalant medicament is sufficient to create a monolayer of the first particulate inhalant medicament on the particulate carrier;
- (b) mixing said first mixture with a second particulate inhalant medicament to form a second mixture; and
- (c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier, and wherein the dry powder inhalation composition consists of said particulate carrier, said first particulate inhalant medicament and said second particulate inhalant medicament.

12. (currently amended) A dry powder inhalation composition according to claim 11, wherein the first particulate inhalant

medicament is budesonide or a pharmaceutically acceptable derivative salt, solvate or salt solvate thereof.

13. (previously presented) A dry powder inhalation composition according to claim 11, wherein the second particulate inhalant medicament is formoterol fumarate dihydrate.

14. (previously presented) A MDPI comprising a composition according to any one of claims 11-13.

15. (previously presented) A method for the administration of a particulate medicament, comprising inhalation from a multidose dry powder inhaler of a composition of any one of claims 11-13.

16. (previously presented) The method of claim 1, wherein the dry powder inhalation composition of step (c) consists of said particulate carrier, said first particulate inhalant medicament and said second particulate inhalant medicament.

17. (previously presented) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 50 to about 60  $\mu\text{m}$ .

18. (previously presented) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 60 to about 90  $\mu\text{m}$ .

19. (previously presented) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 90 to about 150  $\mu\text{m}$ .